Cargando…

Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats

Intestinal microbiota mediate toxicity of irinotecan (CPT-11) cancer therapies and cause systemic infection after CPT-11-induced loss of barrier function. The intestinal microbiota and their functions are thus potential targets for treatment to mitigate CPT-11 toxicity. However, microbiota changes d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xiaoxi B., Dieleman, Levinus A., Ketabi, Ali, Bibova, Ilona, Sawyer, Michael B., Xue, Hongyu, Field, Catherine J., Baracos, Vickie E., Gänzle, Michael G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406026/ https://www.ncbi.nlm.nih.gov/pubmed/22844397 http://dx.doi.org/10.1371/journal.pone.0039764

Ejemplares similares

The Role of Intestinal Microbiota in Development of Irinotecan Toxicity and in Toxicity Reduction through Dietary Fibres in Rats
por: Lin, Xiaoxi B., et al.
Publicado: (2014)

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy
por: Xue, H, et al.
Publicado: (2009)

Chemically Defined Diet Alters the Protective Properties of Fructo-Oligosaccharides and Isomalto-Oligosaccharides in HLA-B27 Transgenic Rats
por: Koleva, Petya, et al.
Publicado: (2014)

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity
por: Levi, Mattan, et al.
Publicado: (2022)

Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.
por: Tsuda, H., et al.
Publicado: (1994)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

Investigation of the Possible Protective Effect of N-Acetylcysteine (NAC) against Irinotecan (CPT-11)-Induced Toxicity in Rats
por: Gençosman, Sevgi, et al.
Publicado: (2022)

Consumption of an omega-3 fatty acids product, INCELL AAFA™, reduced side-effects of CPT-11 (irinotecan) in mice
por: Hardman, W E, et al.
Publicado: (2002)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts
por: Honorat, Mylène, et al.
Publicado: (2015)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
por: Freyer, G, et al.
Publicado: (2000)

A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
por: Bathe, Oliver F, et al.
Publicado: (2009)

Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
por: Woo, Jong Kyu, et al.
Publicado: (2015)

Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects
por: Hardman, W E, et al.
Publicado: (1999)

Protective Effects of Kampo Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrochloride (CPT‐11), in Rats
por: Takasuna, Kiyoshi, et al.
Publicado: (1995)

Irinotecan (CPT-11) Canonical Anti-Cancer Drug Can also Modulate Antiviral and Pro-Inflammatory Responses of Primary Human Synovial Fibroblasts
por: Dobi, Anthony, et al.
Publicado: (2021)

The Gut Microbiota in Celiac Disease and Probiotics
por: Chibbar, Richa, et al.
Publicado: (2019)

CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues
por: Guichard, S, et al.
Publicado: (1999)

Diet and Environment Shape Fecal Bacterial Microbiota Composition and Enteric Pathogen Load of Grizzly Bears
por: Schwab, Clarissa, et al.
Publicado: (2011)

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway
por: Liu, Shasha, et al.
Publicado: (2018)

The “Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer”
por: Deng, Yanhong
Publicado: (2021)

Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer
por: Klassen, Pamela N., et al.
Publicado: (2023)

Manipulation of Gut Microbiota as a Key Target for Crohn's Disease
por: Rashed, Reem, et al.
Publicado: (2022)

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer
por: Tsuda, H, et al.
Publicado: (2004)

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
por: Vassal, G., et al.
Publicado: (1996)

The transcriptomic response to irinotecan in colon carcinoma bearing mice preconditioned by fasting
por: Jongbloed, Franny, et al.
Publicado: (2019)

Effect of CPT‐11 on Lipid Peroxide Level in Mouse Tissues
por: Sadzuka, Yasuyuki, et al.
Publicado: (1997)

Green tea extract prevents CPT-11-induced diarrhea by regulating the gut microbiota
por: Kon, Risako, et al.
Publicado: (2023)

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
por: Masuda, N., et al.
Publicado: (1998)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Pitfalls in defining and quantifying cachexia
por: Baracos, Vickie E.
Publicado: (2011)

Psoas as a sentinel muscle for sarcopenia: a flawed premise
por: Baracos, Vickie E.
Publicado: (2017)

Comparative genomics Lactobacillus reuteri from sourdough reveals adaptation of an intestinal symbiont to food fermentations
por: Zheng, Jinshui, et al.
Publicado: (2015)

Case report: Desmoid fibromatosis diagnosed in a 27-year-old male after being mistaken for a gastrointestinal stromal tumour
por: Albino, Larissa, et al.
Publicado: (2022)

Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
por: Ali, Raafi, et al.
Publicado: (2016)

Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11
por: Araki, Eiji, et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_71uqvsu12uvb9b4776meiv9se2